» Articles » PMID: 35204164

Molecular Mechanisms and Therapeutic Potential of α- and β-Asarone in the Treatment of Neurological Disorders

Overview
Date 2022 Feb 25
PMID 35204164
Authors
Affiliations
Soon will be listed here.
Abstract

Neurological disorders are important causes of morbidity and mortality around the world. The increasing prevalence of neurological disorders, associated with an aging population, has intensified the societal burden associated with these diseases, for which no effective treatment strategies currently exist. Therefore, the identification and development of novel therapeutic approaches, able to halt or reverse neuronal loss by targeting the underlying causal factors that lead to neurodegeneration and neuronal cell death, are urgently necessary. Plants and other natural products have been explored as sources of safe, naturally occurring secondary metabolites with potential neuroprotective properties. The secondary metabolites α- and β-asarone can be found in high levels in the rhizomes of the medicinal plant (L.). α- and β-asarone exhibit multiple pharmacological properties including antioxidant, anti-inflammatory, antiapoptotic, anticancer, and neuroprotective effects. This paper aims to provide an overview of the current research on the therapeutic potential of α- and β-asarone in the treatment of neurological disorders, particularly neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), as well as cerebral ischemic disease, and epilepsy. Current research indicates that α- and β-asarone exert neuroprotective effects by mitigating oxidative stress, abnormal protein accumulation, neuroinflammation, neurotrophic factor deficit, and promoting neuronal cell survival, as well as activating various neuroprotective signalling pathways. Although the beneficial effects exerted by α- and β-asarone have been demonstrated through in vitro and in vivo animal studies, additional research is required to translate laboratory results into safe and effective therapies for patients with AD, PD, and other neurological and neurodegenerative diseases.

Citing Articles

Neuroprotection in traumatic brain injury: effects of alpha-asarone and Acorus calamus extract in mice using weight drop model.

Kalra S, Sachdeva H, Pant A, Singh G Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 40080151 DOI: 10.1007/s00210-025-03977-4.


The spectrum-efficacy correlation of Kai-Xin-San for cognition of Aβ transgenic and verification of its active ingredients.

Wu J, Sun H, Zhao Y, Lian L, Bian H, Guo Y Front Pharmacol. 2025; 16:1538837.

PMID: 39936091 PMC: 11811076. DOI: 10.3389/fphar.2025.1538837.


Long-Term Intracranial Progression-Free Survival in Lung Cancer Brain Metastases Extended Beyond 50 Months with Gubenxiaoyi Formula (GBXY): A Groundbreaking Case Study.

Yang Z, Li H, Chen L, Li S, Chen D, Lu T Integr Cancer Ther. 2025; 24:15347354241313334.

PMID: 39882758 PMC: 11780649. DOI: 10.1177/15347354241313334.


β-Asarone regulates microglia polarization to alleviate TBI-induced nerve damage via Fas/FasL signaling axis.

Xia M, Yi M, Guo C, Xie Y, Yu W, Wang D Hum Cell. 2024; 38(1):33.

PMID: 39718669 DOI: 10.1007/s13577-024-01161-z.


Huanshaodan regulates microglial glucose metabolism reprogramming to alleviate neuroinflammation in AD mice through mTOR/HIF-1α signaling pathway.

Shang C, Su Y, Ma J, Li Z, Wang P, Ma H Front Pharmacol. 2024; 15:1434568.

PMID: 39130642 PMC: 11310104. DOI: 10.3389/fphar.2024.1434568.


References
1.
Chellian R, Pandy V, Mohamed Z . Biphasic Effects of α-Asarone on Immobility in the Tail Suspension Test: Evidence for the Involvement of the Noradrenergic and Serotonergic Systems in Its Antidepressant-Like Activity. Front Pharmacol. 2016; 7:72. PMC: 4811860. DOI: 10.3389/fphar.2016.00072. View

2.
Jellinger K . Cell death mechanisms in neurodegeneration. J Cell Mol Med. 2002; 5(1):1-17. PMC: 6737760. DOI: 10.1111/j.1582-4934.2001.tb00134.x. View

3.
Tatton W, Olanow C . Apoptosis in neurodegenerative diseases: the role of mitochondria. Biochim Biophys Acta. 1999; 1410(2):195-213. DOI: 10.1016/s0005-2728(98)00167-4. View

4.
Dong Z, Wolfer D, Lipp H, Bueler H . Hsp70 gene transfer by adeno-associated virus inhibits MPTP-induced nigrostriatal degeneration in the mouse model of Parkinson disease. Mol Ther. 2004; 11(1):80-8. DOI: 10.1016/j.ymthe.2004.09.007. View

5.
Xiao X, Xu X, Li F, Xie G, Zhang T . Anti-inflammatory treatment with β-asarone improves impairments in social interaction and cognition in MK-801 treated mice. Brain Res Bull. 2019; 150:150-159. DOI: 10.1016/j.brainresbull.2019.05.017. View